{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:53:18Z","timestamp":1788274398037,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.survophthal.2017.08.008","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:02:42Z","timestamp":1504569762000},"page":"281-295","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4179-9141","authenticated-orcid":false,"given":"Peter","family":"Bracha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas A.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Ciulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3335-2948","authenticated-orcid":false,"given":"Darrell","family":"WuDunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6722-4226","authenticated-orcid":false,"given":"Louis B.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib1","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0002-9394(84)90316-7","article-title":"Argon laser photocoagulation for macular edema in branch vein occlusion. The Branch Vein Occlusion Study Group","volume":"98","year":"1984","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1089\/jop.2009.0076","article-title":"Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections","volume":"26","author":"Adelman","year":"2010","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.jcjo.2014.11.004","article-title":"Repeated intravitreal anti-vascular endothelial growth factor injections can induce iatrogenic ocular hypertension, especially in patients with open-angle glaucoma","volume":"50","author":"Agard","year":"2015","journal-title":"Can J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib4","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/IAE.0000000000000371","article-title":"Intraocular pressure trends after intravitreal injections of anti-vascular endothelial growth factor agents for diabetic macular edema","volume":"35","author":"Al-Abdullah","year":"2015","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib5","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3928\/1542-8877-19970401-15","article-title":"Infectious keratitis in a paracentesis tract","volume":"28","author":"Azuara-Blanco","year":"1997","journal-title":"Ophthalmic Surg Lasers"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/15569527.2015.1124886","article-title":"Long-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"35","author":"Baek","year":"2016","journal-title":"Cutan Ocul Toxicol"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib7","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","article-title":"Intravitreal silicone oil droplets after intravitreal drug injections","volume":"28","author":"Bakri","year":"2008","journal-title":"Retina"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00417-008-0819-2","article-title":"Persisent ocular hypertension following intravitreal ranibizumab","volume":"246","author":"Bakri","year":"2008","journal-title":"Graefe's archive Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib9","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2013.11.029","article-title":"Intraocular pressure in eyes receiving monthly ranibizumab in 2 pivotal age-related macular degeneration clinical trials","volume":"121","author":"Bakri","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib10","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.eye.6702938","article-title":"Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab","volume":"23","author":"Bakri","year":"2009","journal-title":"Eye (London, England)"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000444395","article-title":"Long-Term Effect of Anti-VEGF Agents on Intraocular Pressure in Age-Related Macular Degeneration","volume":"56","author":"Beato","year":"2016","journal-title":"Ophthalmic Res"},{"issue":"11","key":"10.1016\/j.survophthal.2017.08.008_bib12","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/bjophthalmol-2013-304075","article-title":"Effect of pegaptanib sodium 0.3 mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study","volume":"98","author":"Boyer","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib13","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","article-title":"Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment","volume":"133","author":"Bressler","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.2165\/00002512-199202030-00005","article-title":"Ocular beta-blockers in glaucoma management. Clinical pharmacological aspects","volume":"2","author":"Brooks","year":"1992","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib15","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology"},{"issue":"14","key":"10.1016\/j.survophthal.2017.08.008_bib16","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib17","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10384-012-0194-8","article-title":"Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length","volume":"57","author":"Cacciamani","year":"2013","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib18","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib19","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/IAE.0b013e318217ffde","article-title":"Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib","volume":"31","author":"Choi","year":"2011","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib20","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1097\/IAE.0000000000000520","article-title":"Sustained Elevation of Intraocular Pressure After Intravitreal Anti-VEGF Agents: What is the evidence?","volume":"35","author":"Dedania","year":"2015","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/02713683.2014.917190","article-title":"The effect of multiple injections of ranibizumab on retinal nerve fiber layer thickness in patients with age-related macular degeneration","volume":"40","author":"Demirel","year":"2015","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib22","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10792-014-9981-1","article-title":"Intraocular pressure changes related to intravitreal injections of ranibizumab: analysis of pseudophakia and glaucoma subgroup","volume":"35","author":"Demirel","year":"2015","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","article-title":"Association of Repeated Intravitreous Bevacizumab Injections With Risk for Glaucoma Surgery","volume":"135","author":"Eadie","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2017.08.008_bib24","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2147\/OPTH.S80704","article-title":"Evaluation of the effect of intravitreal ranibizumab injections in patients with neovascular age related macular degeneration on retinal nerve fiber layer thickness using optical coherence tomography","volume":"9","author":"El-Ashry","year":"2015","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib25","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000446878","article-title":"Intraocular Pressure Spikes after Aflibercept Intravitreal Injections","volume":"236","author":"El Chehab","year":"2016","journal-title":"Ophthalmologica"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib26","doi-asserted-by":"crossref","first-page":"277","DOI":"10.5301\/ejo.5000159","article-title":"Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection","volume":"23","author":"El Chehab","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib27","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2010.12.033","article-title":"Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema","volume":"118","author":"Elman","year":"2011","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib28","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4103\/2008-322X.150815","article-title":"Changes in Retinal Nerve Fiber Layer Thickness after Two Intravitreal Bevacizumab Injections for Wet Type Age-related Macular Degeneration","volume":"9","author":"Entezari","year":"2014","journal-title":"J\u00a0Ophthalmic Vis Res"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib29","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1083\/jcb.140.4.947","article-title":"Vascular endothelial growth factor induces endothelial fenestrations in\u00a0vitro","volume":"140","author":"Esser","year":"1998","journal-title":"J\u00a0Cell Biol"},{"issue":"8","key":"10.1016\/j.survophthal.2017.08.008_bib30","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1097\/IAE.0b013e3180592ba6","article-title":"Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin)","volume":"27","author":"Falkenstein","year":"2007","journal-title":"Retina (Philadelphia, Pa)"},{"key":"10.1016\/j.survophthal.2017.08.008_bib31","doi-asserted-by":"crossref","first-page":"599","DOI":"10.2147\/OPTH.S58413","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab in diabetic retinopathy patients","volume":"8","author":"Farhood","year":"2014","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"key":"10.1016\/j.survophthal.2017.08.008_bib32","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/bjophthalmol-2015-307595","article-title":"Changes in intraocular pressure in study and fellow eyes in the IVAN trial","volume":"100","author":"Foss","year":"2016","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ajo.2007.01.052","article-title":"Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma","volume":"143","author":"Frenkel","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/j.ophtha.2015.04.018","article-title":"Intraocular Pressure in Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Aflibercept or Ranibizumab","volume":"122","author":"Freund","year":"2015","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib35","doi-asserted-by":"crossref","first-page":"e0161332","DOI":"10.1371\/journal.pone.0161332","article-title":"Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility","volume":"11","author":"Fujimoto","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.survophthal.2017.08.008_bib36","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ncb1486","article-title":"VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin","volume":"8","author":"Gavard","year":"2006","journal-title":"Nat Cell Biol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/bjo.2008.138479","article-title":"Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin)","volume":"93","author":"Georgopoulos","year":"2009","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib38","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1097\/IJG.0b013e31819c4893","article-title":"Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure","volume":"18","author":"Gismondi","year":"2009","journal-title":"J\u00a0Glaucoma"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib39","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/15569527.2012.696569","article-title":"Short-term impact of intravitreal ranibizumab injection on axial ocular dimension and intraocular pressure","volume":"32","author":"Goktas","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"issue":"8","key":"10.1016\/j.survophthal.2017.08.008_bib40","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/bjo.2010.180729","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents","volume":"95","author":"Good","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"27","key":"10.1016\/j.survophthal.2017.08.008_bib41","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib42","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/00061198-199708000-00010","article-title":"Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment","volume":"6","author":"Greenfield","year":"1997","journal-title":"J\u00a0Glaucoma"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib43","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/17425247.2012.685155","article-title":"Randomized clinical trial of two anesthetic techniques for intravitreal injections: 4% liquid lidocaine on cotton swabs versus 3.5% lidocaine gel","volume":"9","author":"Gregori","year":"2012","journal-title":"Expert Opin Drug Deliv"},{"issue":"12","key":"10.1016\/j.survophthal.2017.08.008_bib44","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib45","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1136\/bjo.79.9.866","article-title":"Bacterial endophthalmitis after anterior chamber paracentesis","volume":"79","author":"Helbig","year":"1995","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib46","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1097\/00055735-200104000-00002","article-title":"Update on topical carbonic anhydrase inhibitors","volume":"12","author":"Herkel","year":"2001","journal-title":"Curr Opin Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/IAE.0000000000000039","article-title":"Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy","volume":"34","author":"Hoang","year":"2014","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ophtha.2011.08.011","article-title":"Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections","volume":"119","author":"Hoang","year":"2012","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/IAE.0b013e318261a6f7","article-title":"Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy","volume":"33","author":"Hoang","year":"2013","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"10","key":"10.1016\/j.survophthal.2017.08.008_bib50","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s00417-010-1382-1","article-title":"Impact of injection techniques on intraocular pressure (IOP) increase after intravitreal ranibizumab application","volume":"248","author":"Hohn","year":"2010","journal-title":"Graefe's archive Clin Exp Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib51","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3129\/i07-172","article-title":"Short-term intraocular pressure changes after intravitreal injection of bevacizumab","volume":"42","author":"Hollands","year":"2007","journal-title":"Can J Ophthalmol J canadien d'ophtalmologie"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib52","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5301\/ejo.5000081","article-title":"Effect of the Honan intraocular pressure\u00a0reducer to prevent vitreous reflux after intravitreal\u00a0bevacizumab injection","volume":"22","author":"Hong","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib53","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ajo.2010.04.029","article-title":"Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy","volume":"150","author":"Horsley","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib54","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ophtha.2015.05.030","article-title":"Anti-Vascular Endothelial Growth Factor Injections and Intraocular Pressure Measurement: Should We Throw the Baby out with the Bath Water?","volume":"122","author":"Jampel","year":"2015","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib55","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/sj.eye.6702734","article-title":"Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases","volume":"22","author":"Jonas","year":"2008","journal-title":"Eye (Lond)"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib56","first-page":"163","article-title":"Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature","volume":"17","author":"Jones","year":"2006","journal-title":"Curr Opin Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib57","first-page":"91","article-title":"Purulent anterior segment endophthalmitis following paracentesis","volume":"17","author":"Joondeph","year":"1986","journal-title":"Ophthalmic Surg"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/IJG.0b013e3181ca74de","article-title":"In\u00a0vitro effects of antivascular endothelial growth factors on cultured human trabecular meshwork cells","volume":"19","author":"Kahook","year":"2010","journal-title":"J\u00a0Glaucoma"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib59","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3928\/15428877-20090430-12","article-title":"Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections","volume":"40","author":"Kahook","year":"2009","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib60","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/IAE.0b013e3181d50cea","article-title":"High-molecular-weight aggregates in repackaged bevacizumab","volume":"30","author":"Kahook","year":"2010","journal-title":"Retina (Philadelphia, Pa)"},{"issue":"11","key":"10.1016\/j.survophthal.2017.08.008_bib61","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00347-007-1569-y","article-title":"[Bevacizumab is not toxic to human anterior- and posterior-segment cultured cells]","volume":"104","author":"Kernt","year":"2007","journal-title":"Ophthalmologe"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib62","doi-asserted-by":"crossref","first-page":"e0137833","DOI":"10.1371\/journal.pone.0137833","article-title":"Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents","volume":"10","author":"Kiddee","year":"2015","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib63","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.survophthal.2012.08.003","article-title":"Intraocular pressure monitoring post intravitreal steroids: a systematic review","volume":"58","author":"Kiddee","year":"2013","journal-title":"Surv Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib64","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3109\/08820538.2012.754479","article-title":"Effect of Dorzolamide\/Timolol or Brinzolamide\/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension","volume":"28","author":"Kim","year":"2013","journal-title":"Semin Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib65","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s10384-011-0088-1","article-title":"Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique","volume":"55","author":"Kim","year":"2011","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib66","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","article-title":"Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents","volume":"146","author":"Kim","year":"2008","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib67","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/IJG.0b013e3182946505","article-title":"Does intravitreal injections of bevacizumab for age-related macular degeneration affect long-term intraocular pressure?","volume":"23","author":"Kim","year":"2014","journal-title":"J\u00a0Glaucoma"},{"issue":"6","key":"10.1016\/j.survophthal.2017.08.008_bib68","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.ajo.2014.02.035","article-title":"Long-term effects of multiple intravitreal antivascular endothelial growth factor injections on intraocular pressure","volume":"157","author":"Kim","year":"2014","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2017.08.008_bib69","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/IAE.0b013e3181aade74","article-title":"Tunnelled versus straight intravitreal injection: intraocular pressure changes, vitreous reflux, and patient discomfort","volume":"29","author":"Knecht","year":"2009","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1755-3768.2010.01904.x","article-title":"Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study","volume":"90","author":"Knip","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib71","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","article-title":"Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model","volume":"85","author":"Kotliar","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"issue":"3-4","key":"10.1016\/j.survophthal.2017.08.008_bib72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000369478","article-title":"Intraocular Pressure in Eyes Receiving Intravitreal Antivascular Endothelial Growth Factor Injections","volume":"233","author":"Lemos","year":"2015","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib73","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000445038","article-title":"Short-Term Visual Acuity and Intraocular Pressure Changes and Their Correlation after Anti-Vascular Endothelial Growth Factor Injection","volume":"236","author":"Lim","year":"2016","journal-title":"Ophthalmologica"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib74","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1167\/iovs.10-6431","article-title":"Silicone oil microdroplets\u00a0and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling","volume":"52","author":"Liu","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1755-3768.2011.02299.x","article-title":"Topical drug delivery to the eye: dorzolamide","volume":"90","author":"Loftsson","year":"2012","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib76","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10792-010-9410-z","article-title":"Sustained ocular hypertension following intravitreal injections of 0.5 mg\/0.05 ml ranibizumab","volume":"31","author":"Loukianou","year":"2011","journal-title":"Int Ophthalmol"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib77","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.survophthal.2017.08.008_bib78","doi-asserted-by":"crossref","first-page":"6214","DOI":"10.1167\/iovs.12-9875","article-title":"Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab","volume":"53","author":"Martinez-de-la-Casa","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"10.1016\/j.survophthal.2017.08.008_bib79","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00417-012-1981-0","article-title":"Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration","volume":"250","author":"Mathalone","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib80","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000446016","article-title":"A\u00a0Case of Sustained Intraocular Pressure Elevation after Multiple Intravitreal Injection of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration","volume":"7","author":"Matsubara","year":"2016","journal-title":"Case Rep Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib81","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1159\/000346397","article-title":"Long-term intraocular pressure changes in patients with neovascular age-related macular degeneration treated with ranibizumab","volume":"229","author":"Menke","year":"2013","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib82","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bjo.2007.126193","article-title":"Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration","volume":"92","author":"Mojica","year":"2008","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2017.08.008_bib83","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/eye.2014.180","article-title":"Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients","volume":"28","author":"Murray","year":"2014","journal-title":"Eye (London, England)"},{"issue":"9","key":"10.1016\/j.survophthal.2017.08.008_bib84","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4103\/0301-4738.194329","article-title":"Long-term effect of anti-vascular endothelial growth factor injections on intraocular pressure","volume":"64","author":"Nariani","year":"2016","journal-title":"Indian J Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib85","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10792-016-0171-1","article-title":"The early effects of intravitreal anti vascular endothelial growth factor agents on intraocular pressure and central corneal thickness","volume":"36","author":"Omay","year":"2016","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib86","first-page":"496","article-title":"Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection","volume":"8","author":"Ozcaliskan","year":"2015","journal-title":"Int J Ophthalmol"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib87","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/jop.2012.0144","article-title":"Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure","volume":"29","author":"Ozkaya","year":"2013","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib88","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1097\/IAE.0000000000000476","article-title":"Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections","volume":"35","author":"Pang","year":"2015","journal-title":"Retina"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib89","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3341\/jkos.2014.55.5.693","article-title":"Changes in the Retinal Nerve Fiber Layer after Intravitreal Injections of Bevacizumab in Glaucoma Patients","volume":"55","author":"Park","year":"2014","journal-title":"J\u00a0Korean Ophthalmol Soc"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib90","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10792-014-9972-2","article-title":"The long-term effect of intravitreal ranibizumab on retinal nerve fiber layer thickness in exudative age-related macular degeneration","volume":"35","author":"Parlak","year":"2015","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.survophthal.2017.08.008_bib91","first-page":"1131","article-title":"Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study","volume":"10","author":"Pece","year":"2016","journal-title":"Clin Ophthalmol (Auckland, NZ)"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib92","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.exer.2011.12.017","article-title":"Protein markers and differentiation in culture for Schlemm's canal endothelial cells","volume":"96","author":"Perkumas","year":"2012","journal-title":"Exp Eye Res"},{"issue":"5","key":"10.1016\/j.survophthal.2017.08.008_bib93","doi-asserted-by":"crossref","first-page":"460","DOI":"10.3928\/23258160-20130909-07","article-title":"Ocular hypertension and intraocular pressure asymmetry after intravitreal injection of anti-vascular endothelial growth factor agents","volume":"44","author":"Pershing","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib94","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/jop.2014.0062","article-title":"High intraocular\u00a0pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism","volume":"31","author":"Ricca","year":"2015","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib95","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00055735-199704000-00008","article-title":"The role of alpha-agonists in glaucoma therapy","volume":"8","author":"Robin","year":"1997","journal-title":"Curr Opin Ophthalmol"},{"issue":"14","key":"10.1016\/j.survophthal.2017.08.008_bib96","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"New Engl J Med"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib97","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","article-title":"Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review","volume":"127","author":"Saylor","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.survophthal.2017.08.008_bib98","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/978-94-007-7359-2_17","article-title":"Glaucoma and the applications of carbonic anhydrase inhibitors","volume":"75","author":"Scozzafava","year":"2014","journal-title":"Subcell Biochem"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib99","first-page":"352","article-title":"Persistent elevation of intraocular pressure following intravitreal injection of bevacizumab","volume":"15","author":"Segal","year":"2013","journal-title":"Isr Med Assoc J"},{"issue":"10","key":"10.1016\/j.survophthal.2017.08.008_bib100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1089\/jop.2016.0014","article-title":"Retinal Nerve Fiber Layer Thickness Changes in Age-Related Macular Degeneration Treated with Multiple Intravitreal Ranibizumab","volume":"32","author":"Sengul","year":"2016","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.survophthal.2017.08.008_bib101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/112067211002000124","article-title":"Course of intraocular pressure after intravitreal injection of 0.05 mL ranibizumab (Lucentis)","volume":"20","author":"Sharei","year":"2010","journal-title":"Eur J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib102","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1167\/iovs.15-18404","article-title":"Intravitreal Anti-Vascular Endothelial Growth Factor Therapy and Retinal Nerve Fiber Layer Loss in Eyes With Age-Related Macular Degeneration: A Meta-Analysis","volume":"57","author":"Shin","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib103","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1167\/iovs.13-13769","article-title":"Change of retinal nerve fiber layer thickness in various retinal diseases treated with multiple intravitreal antivascular endothelial growth factor","volume":"55","author":"Shin","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib104","doi-asserted-by":"crossref","first-page":"328","DOI":"10.3928\/15428877-20120618-01","article-title":"Glaucoma filtration\u00a0surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF\u00a0injections","volume":"43","author":"Skalicky","year":"2012","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"10.1016\/j.survophthal.2017.08.008_bib105","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2174\/1874364101004010028","article-title":"Sustained intraocular pressure elevation after intravitreal injection of bevacizumab and ranibizumab associated with trabeculitis","volume":"4","author":"Sniegowski","year":"2010","journal-title":"Open Ophthalmol J"},{"issue":"2","key":"10.1016\/j.survophthal.2017.08.008_bib106","first-page":"211","article-title":"Effects of multiple intravitreal anti-VEGF injections on retinal nerve fiber layer and intraocular pressure: a comparative clinical study","volume":"6","author":"Sobaci","year":"2013","journal-title":"Int J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib107","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1055\/s-0029-1245201","article-title":"Effect of brimonidine\/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab","volume":"227","author":"Theoulakis","year":"2010","journal-title":"Klin Monbl Augenheilkund"},{"issue":"12","key":"10.1016\/j.survophthal.2017.08.008_bib108","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","article-title":"Effects of brimonidine on aqueous humor dynamics in human eyes","volume":"113","author":"Toris","year":"1995","journal-title":"Arch Ophthalmol"},{"issue":"8","key":"10.1016\/j.survophthal.2017.08.008_bib109","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1442-9071.2011.02565.x","article-title":"Safety profile of anterior chamber paracentesis performed at the slit lamp","volume":"39","author":"Trivedi","year":"2011","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2017.08.008_bib110","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/IJG.0b013e31820d7d19","article-title":"Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"21","author":"Tseng","year":"2012","journal-title":"J\u00a0Glaucoma"},{"issue":"7","key":"10.1016\/j.survophthal.2017.08.008_bib111","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/IAE.0b013e31823f0c95","article-title":"A\u00a0lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab","volume":"32","author":"Wehrli","year":"2012","journal-title":"Retina"},{"issue":"3","key":"10.1016\/j.survophthal.2017.08.008_bib112","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1167\/iovs.16-20786","article-title":"Intravitreal Anti-VEGF Injections Reduce Aqueous Outflow Facility in Patients With Neovascular Age-Related Macular Degeneration","volume":"58","author":"Wen","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"11","key":"10.1016\/j.survophthal.2017.08.008_bib113","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.oftal.2010.09.010","article-title":"[Immediate changes in intraocular pressure after an intravitreal injection of 2.5 mg of bevacizumab]","volume":"85","author":"Wu","year":"2010","journal-title":"Arch Soc Esp Oftalmol"},{"key":"10.1016\/j.survophthal.2017.08.008_bib114","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2147\/OPTH.S58410","article-title":"Evaluation of intraocular pressure elevation after multiple injections of intravitreal ranibizumab","volume":"8","author":"Yu","year":"2014","journal-title":"Clin Ophthalmol"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717301145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625717301145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:44:36Z","timestamp":1758541476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625717301145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0039625717301145"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2017.08.008","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2017.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}